Herpes Labialis (Oral Herpes) drugs in development, 2023

GlobalData tracks 15 drugs in development for Herpes Labialis (Oral Herpes) by 11 companies/universities/institutes. The top development phase for Herpes Labialis (Oral Herpes) is preclinical, with six drugs in that stage.

Cityblock Expands Access for High-Risk Medicaid Members in Ohio

What You Should Know: – Buckeye Health Plan and Cityblock are teaming up to provide integrated, community-based care to approximately 10,000 underserved Medicaid recipients in

January 9, 2024

Study finds link between poor mental health and browsing negative online content

People with poorer mental health are more prone to browsing negative content online, which further exacerbates their symptoms, finds a study led by UCL researchers.

November 21, 2024

Lexicon plans another bid for Zynquista in type 1 diabetes

Lexicon’s Zynquista (sotagliflozin) is an oral dual inhibitor of the sodium-dependent glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). Image Credit: MacroEcon / Shutterstock.

May 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.